Analysis of the clinicopathologic features and prognosis in triple-negative breast cancer
- First Online:
- Cite this article as:
- Yang, D., Liu, H. & Zhao, J. Chin. J. Clin. Oncol. (2008) 5: 387. doi:10.1007/s11805-008-0387-6
- 16 Downloads
To investigate the clinical and pathological features, as well as prognosis in triple-negative breast cancer patients.
A total of 509 cases of operable breast cancer from January, 2002 to June, 2002 treated in the Cancer Hospital of Tianjin Medical University were analyzed. The Her-2, ER and PR status was determined using immunohistochemistry. Of the total cases, one group was identified as triple negative breast cancer, ie defined as ER, PR and Her-2 negative. The other group was non-triple-negative breast cancer. Clinicopathologic features of the groups were compared and 5-year disease-free survival (DFS) analyzed by the Kaplan-Meier method.
Of the total cases, 21.4% (109/509) of cases were found to be triple-negative while 78.6% (400/509) were non-triple-negative. The triple negative group had higher incidence rates than the non-triple-negative group of the medullary type and Grade III tumors (P < 0.05). There was no other difference in the clinicopathologic features between the 2 groups. From follow-up to June, 2007, 21.1% (23/109) of the triple-negative group and 12.7% (51/400) of the non-triple negative group had a local recurrence or distant metastasis, resulting in a significant difference (P < 0.05). In the triple-negative group and non-triple-negative group, 5-year DFS were 78.9% and 87.3% respectively. There was a statistically significant difference between the 2 groups (P = 0.031).
Compared with non-triple-negative breast cancer, triple-negative breast cancer patients have an increased likehood of a local recurrence or distant metastasis and a poorer prognosis.